Gapping up
In reaction to earnings/guidance:
- LOVE +17.8%, DNA +7%, JEF +4.5%, TBLA +1.6%
Other news:
- IGMS +37.5% (IGM Biosciences and Sanofi announce collaboration agreement for oncology immunology and inflammation targets; also reported earnings)
- NLSN +20.9% (enters into agreement to be acquired by Evergreen and Brookfield (BBU) consortium for $16 bln)
- EVTL +13.3% (Avolon exceeds pre-order commitments)
- LHCG +7.3% (LHC Group and Optum have agreed to combine to further strengthen their shared ability to advance value-based care especially in the comfort of a patient's own home)
- LHDX +5.5% (Lucira Health COVID-19 & flu at-home molecular test shows positive clinical study results)
- BHLB +4.9% (expands partnership with FinTech firm Narmi to enhance its digital banking experience)
- TSHA +4.3% (announces the initiation of clinical development of TSHA-102 for the treatment of Rett syndrome under a recently approved Clinical Trial Application by Health Canada)
- NVO +3.1% (FDA approves 2.0 mg dose of Ozempic)
- BCS +2.8% (provides impact of over-issuance under BBPLC US shelf; Barclays expects the rescission losses (net of tax) to be GBP 450 mln)
- STNG +2.5% (enters into MoU with Carbon Ridge to develop onboard carbon capture)
- FDX +2.3% (Raj Subramaniam to become new CEO)
- HBM +1.4% (provides annual reserve and resource update)
- AZN +1.1% (Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors)
Analyst comments:
- HMLP +3.5% (upgraded to Buy from Hold at Stifel)
- FTNT +2.6% (upgraded to Overweight from Equal Weight at Barclays)
- CUBI +1.9% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)